Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 13/20 | 0.53 |
| ▸ | CCND1 | P24385 | 13/20 | 0.53 |
| ▸ | CCND2 | P30279 | 12/20 | 0.53 |
| ▸ | CCND3 | P30281 | 12/20 | 0.53 |
| ▸ | PLK2 | Q9NYY3 | 6/20 | 0.50 |
| ▸ | FGFR3 | P22607 | 3/20 | 0.49 |
| ▸ | LCK | P06239 | 1/20 | 0.49 |
| ▸ | KIT | P10721 | 1/20 | 0.49 |
| ▸ | FLT3 | P36888 | 1/20 | 0.49 |
| ▸ | PLK1 | P53350 | 1/20 | 0.49 |
| ▸ | RPS6KA1 | Q15418 | 1/20 | 0.49 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.49 |
| ▸ | WNK2 | Q9Y3S1 | 1/20 | 0.49 |
| ▸ | NEK2 | P51955 | 1/20 | 0.47 |
| ▸ | NEK5 | Q6P3R8 | 1/20 | 0.47 |
| ▸ | NEK1 | Q96PY6 | 1/20 | 0.47 |
| ▸ | CCNA2 | P20248 | 3/20 | 0.46 |
| ▸ | CDK2 | P24941 | 3/20 | 0.46 |
| ▸ | AURKA | O14965 | 1/20 | 0.46 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6813162 | 0.91 | CDK4 (0.66) | CDK4CCND1CCND2CCND3PLK2 | |
| SCHEMBL6812338 | 0.89 | CDK4 (0.64) | CDK4CCND1CCND2CCND3PLK2 | |
| SCHEMBL6808715 | 0.85 | CDK4 (0.54) | CDK4CCND1CCND2CCND3FGFR3 | |
| SCHEMBL6803962 | 0.85 | CDK4 (0.64) | CDK4CCND1CCND2CCND3FGFR3 | |
| SCHEMBL6807725 | 0.83 | PLK2 (0.62) | CDK4CCND1CCND2CCND3PLK2 | |
| SCHEMBL6812408 | 0.83 | CDK4 (0.65) | CDK4CCND1CCND2CCND3PLK2 | |
| SCHEMBL6809009 | 0.83 | CDK4 (0.54) | CDK4CCND1CCND2CCND3FGFR3 | |
| SCHEMBL6803548 | 0.82 | CDK4 (0.58) | CDK4CCND1CCND2CCND3FGFR3 | |
| SCHEMBL6808048 | 0.82 | CDK4 (0.56) | CDK4CCND1CCND2CCND3FGFR3 | |
| SCHEMBL6917568 | 0.81 | CDK4 (0.57) | CDK4CCND1CCND2CCND3FGFR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040224958-A1 | Pyridopyrimidinone derivatives for treatment of neurodegenerative disease | BOOTH RICHARD JOHN (US) | 2004-11-11 | — | — | US | claimed |
| US-20040224958-A1 | Pyridopyrimidinone derivatives for treatment of neurodegenerative disease | BOOTH RICHARD JOHN (US) | 2004-11-11 | — | — | US | disclosed |
| EP-1255755-A1 | PYRIDOPYRIMIDINONE DERIVATIVES FOR TREATMENT OF NEURODEGENERATIVE DISEASE | WARNER-LAMBERT COMPANY (US) | 2002-11-13 | — | — | EP | disclosed |
| WO-2001055148-A1 | PYRIDOPYRIMIDINONE DERIVATIVES FOR TREATMENT OF NEURODEGENERATIVE DISEASE | WARNER-LAMBERT COMPANY (US) | 2001-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040224958-A1 | Pyridopyrimidinone derivatives for treatment of neurodegenerative disease | CDK4, CDKL1, CCNT1 | CDK4 1/4885CCND1 23/4885CCND2 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.